Clinically Relevant Benefits Seen for GLP-1RA, SGLTi Treatment of T1DM
THURSDAY, March 2, 2023 -- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are beneficial for treating type 1 diabetes mellitus (T1DM), with similar reductions in glycated hemoglobin A1c...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Pharmaceuticals | Sodium